- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Decreases By 13.5% | 2 | MarketBeat | ||
| 14.11. | Belite Bio stock soars to all-time high of $84.2 amid robust gains | 1 | Investing.com | ||
| 14.11. | Belite Bio-Aktie erreicht Rekordhoch von 84,20 US-Dollar | 2 | Investing.com Deutsch | ||
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| 12.11. | Belite Bio, Inc: Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | 83 | GlobeNewswire (Europe) | Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects... ► Artikel lesen | |
| 11.11. | Insights into Belite Bio's Upcoming Earnings | 1 | Benzinga.com | ||
| 06.11. | Belite Bio (BLTE) Scheduled to Post Earnings on Tuesday | 2 | MarketBeat | ||
| 05.11. | Belite Bio, Inc: Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results | 3 | GlobeNewswire (USA) | ||
| 04.11. | Belite Bio stock soars to all-time high of $70.4 amid robust growth | 1 | Investing.com | ||
| 04.11. | Belite Bio-Aktie erreicht Allzeithoch von 70,4 US-Dollar | 2 | Investing.com Deutsch | ||
| 04.11. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.11. | Belite Bio, Inc: Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds | 1 | GlobeNewswire (USA) | ||
| 28.10. | Belite Bio-Aktie erreicht Allzeithoch von 67,6 US-Dollar | - | Investing.com Deutsch | ||
| 28.10. | Belite Bio stock soars to all-time high of $67.6 amid robust gains | 1 | Investing.com | ||
| 18.10. | Belite Bio stock soars to all-time high of $56.62 | 1 | Investing.com | ||
| 18.10. | Belite Bio-Aktie erreicht Allzeithoch von 56,62 US-Dollar | 2 | Investing.com Deutsch | ||
| 10.10. | Belite Bio-Aktie erreicht Allzeithoch von 55,68 US-Dollar | 2 | Investing.com Deutsch | ||
| 10.10. | Belite Bio stock soars to all-time high of $55.68 | 1 | Investing.com | ||
| 03.10. | Belite Bio-Aktie erreicht Allzeithoch von 50,69 US-Dollar | 3 | Investing.com Deutsch | ||
| 03.10. | Belite Bio stock soars to all-time high of $50.69 | 1 | Investing.com | ||
| 01.10. | BELITE BIO, INC - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARGENX | 549,20 | -2,03 % | argenx SE: argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies | Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for efgartigimod... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| EVOTEC | 9,915 | +0,10 % | Evotec: Extreme Ausschläge | Größer könnten die Gegensätze wohl kaum sein. Die Aktie von Evotec hat im zurückliegenden Jahren einen massiven Einbruch erfahren. Auf 52-Wochen-Sicht gehört sie zu den schlechtesten Aktien im SDAX.... ► Artikel lesen | |
| QIAGEN | 39,900 | +2,73 % | DAX fehlen die Impulse. Qiagen deutet Gegenbewegung an | ||
| QUANTUM-SI | 1,400 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
| 89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
| DYNE THERAPEUTICS | 30,000 | 0,00 % | Dyne Therapeutics: Leitender Vizepräsident veräußert Aktien im Wert von 77.127 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) |
Das Unternehmen BELITE BIO INC ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 77,00 Euro und damit -1,28 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.
